disease. purkinje cells in sca1 mice also undergo age-dependent alterations in mitochondrial morphology. in addition, purkinje cells of sca1 mice have impaired electron transport complexes and decreased atpase activity. the sca1 mice experience increased oxidative stress and increased oxidative dna damage. the mitochondrial targeted antioxidant mitoq was found to slow down the appearance of sca1-linked neuropathologies such as lack of motor coordination. mitoq also prevented oxidative stress induced dna damage and purkinje cell loss. cell replacement therapies one treatment option being investigated is stem cell therapy, which attempts to replace dead tissue by transplanting stem cells into affected region and either stimulating them to differentiate into the desired cell types or allowing them to stimulate endogenous regenerative mechanisms. these techniques are of interest to researchers as a possible treatment for neurodegenerative diseases, but currently are of limited success in animal models, and in in-vitro cell culture studies. the ability for grafted cells to integrate into the desired tissue and adjust for the unique pathologies of different neurodegenerative disorders can be a severe limitation on the development of stem cell based treatments. further, the tissues in the brain often rely on intricate and complicated arrangements of neurons; regions of the brain that do not require precision in these patterns to function, like the striatum affected by parkinson's disease which uses paracrine signaling, tend to have better results in stem cell therapies than systems that require precision, like the cerebellum and pons. stem cell therapies can be especially difficult in replacing purkinje neuron loss as unaffected granule cells can prevent axons reaching the deep cerebellar nuclei with which purkinje cells interface. despite these difficulties, grafted neural precursor cells have been shown to be viable and to successfully migrate into desired location in sca1 transgenic mice models and mesenchymal stem cells have been shown to mitigate loss of dendritic arborization sca1 mice. positive results have been found in mice models using both stem cells from fetal neuroectoderm and adult stem cells from the lateral ventricles and the dentate gyrus.: 177–188 using harvested stem cells in stem cell therapies require immunosuppression to prevent the host from rejecting the transplants; creating induced pluripotent stem cells from the host's own cells would mitigate this risk and has had some testing in other neurodegenerative diseases.: 177–188